NeoDynamics – Q&A session with CEO Anna Eriksrud
In this Q&A session, we will focus on the FDA’s approval of NeoDynamics innovative pulse biopsy system NeoNavia™.
The US market is potentially the largest and is estimated to reach $830 million by 2025.
Feel free to ask questions during the presentation.
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing the diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients. NeoDynamic´s share is listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD).
*Disclaimer: HC Andersen Capital receives payment from the company for a Digital IR / Corporate Visibility subscription agreement. The content does not make recommendations to buy, sell or hold. HC Andersen Capital is an information platform that connects investors and listed companies.